Publications

A growing body of evidence supports vWF inhibition as a therapeutic strategy in thrombosis

ESOC 2025

BB-031 in acute treatment: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in Acute Ischemic Stroke - The RAISE trial

May 21, 2025

Drug Discovery Online

Targeting Von Willebrand Factor With An RNA Aptamer To Treat Stroke

June 6, 2023

Stroke

Aptamer Inhibitor of Von Willebrand Factor Induces Thrombolysis and Improves Vascular Patency Upon Immediate and Delayed Treatment of Stroke in an in vitro Microfluidic Model

February 2, 2023

Pharmaceuticals

Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion

November 22, 2022

ISTH 2022

Effect of Novel Thrombolytic Aptamer BB-031 on Microfluidic Thrombolysis and VWF Function Dose-Response

July 9, 2022

2022 International Stroke Conference

vWF Inhibitor Lyses Middle Cerebral Artery Occlusion After 6 Hours Of Large Vessel Occlusion Stroke

February 3, 2022

2020 International Stroke Conference

vWF Inhibitor Lyses Middle Cerebral Artery Occlusion After 6 Hours Of Large Vessel Occlusion Stroke

February 12, 2020

Frontiers In Immunology

von Willebrand Factor and Platelet Glycoprotein Ib: A Thromboinflammatory Axis in Stroke

December 16, 2019

Molecular Therapy

Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels

July 3, 2019

Arteriosclerosis Thrombosis and Vascular Biology

VWF Inhibition by an RNA Aptamer Improves Functional Outcome Compared to rTPA in Ferric Chloride-induced Carotid Artery Thrombosis in Mice

March 12, 2019

Circulation

Translating Thrombolytic Efficacy of Von Willebrand Factor Aptamer Inhibition From a Small to Large Animal Model of Carotid Occlusion

June 9, 2018

Stroke

Aptamer Inhibition of Von Willebrand Factor Ameliorates Ischemic Stroke Burden in a Murine Model of Thromboembolic Stroke

January 22, 2018

Stroke

Reversible Aptamer Inhibition of Von Willebrand Factor is a Potent Thrombolytic and Ameliorates Stroke Burden Following Vascular Injury Compared to Recombinant Tissue Plasminogen Activator

February 21, 2017

Molecular Therapy

Rapidly Regulating Platelet Activity In Vivo With an Antidote Controlled Platelet Inhibitor

February 1, 2012

Oligonucleotides

Antidote-Controlled Platelet Inhibition Targeting von Willebrand Factor with Aptamers

September 13, 2007